Share

EBCC11 – THE meeting for breast cancer specialists!

The European Breast Cancer Conference is a multidisciplinary meeting attracting leading breast cancer specialists from all over the world. In 2018, EBCC 11 will be held from 21 to 23rd March in Barcelona, Spain.

Organised by the European Breast Cancer Council, of which EORTC Breast Cancer Group, EUSOMA (European Society of Breast Cancer Specialists) and Europa Donna (a patient advocacy organisation) are members, this conference began in 1990s when, the EORTC Breast Cancer Group Chair, Professor Umberto Veronesi envisioned that EORTC should present its results to the European breast cancer community at large. He believed, in this way, information is disseminated directly to a multidisciplinary audience, which would then have a faster impact on breast cancer patients’ outcome and quality of life. Following discussions with EUSOMA and Europa Donna, EBCC was born and the first meeting was held in Florence in 1998. From its initiation, the conference has grown from 2000 to 5000 participants at its peak and it has become an important event for all stakeholders involved in breast cancer.

“This conference is unique, you have the current knowledge on breast cancer care  in one place at one time, while updating you on the latest information,” says Professor Emiel Rutgers, President of European Breast Cancer Council, member of the EORTC Breast Cancer Group, surgeon at the Netherlands Cancer Institute in Amsterdam. “For a breast cancer specialist, this is the “must attend” meeting in Europe.”

EBCC returns to Barcelona for the third time and this edition will again host very educational and extremely interactive sessions. You will be able to discuss challenging issues with a panel of eminent experts from round the world. Participate in exciting debates, asking thought provoking questions. There will be well known specialists presenting keynote lectures on their current research.

Professor Jose Baselga, an eminent medical oncologist from Memorial Sloan Kettering Cancer Centre in USA, has been awarded the European Breast Cancer Science Award and he will present the Emmanuel van der Scheuren Lecture. Professor Andrew Tutt from the Institute of Cancer Research in UK, will present his latest research on PARP inhibitors and Professor Nadia Harbeck from University of Munich in Germany will present her view on whether we will be able to predict response for any treatment in 2018.

The conference is renowned for discussing practical solutions for managing difficult cases to achieve better outcomes. The “Best Practice” sessions on topics like Adjuvant Chemotherapy in the Older Patient and Male Breast Cancer: New sights really highlight the challenges and present how to manage these patients.

EBCC also attracts the attention of media, as there are numerous presentations of brand new practice changing trials achieving a global outreach from the data presented at the conference.

“EBCC 11 offers a number of opportunities for breast cancer specialists to be involved in the conference, there are slots for oral and poster presentations as well as being able to meet leading experts to discuss cases,” says Dr Etienne Brain, Chair of the EORTC Breast Cancer Group and a medical oncologist at Institut Curie in Saint-Cloud and Paris. “Debate sessions and clinical symposium will identify missing pieces of the puzzle and highlight the strong need for multidisciplinarity at all levels. Being European by essence, EBCC offers a unique stage to address diversity and to diminish inequalities of access to health cares across countries, for the greater benefit of our patients. This cannot happen without sharing experiences, new research data, emerging concepts, and creative models. To be practice changing, let us be practice sharing!”

To participate and present, please go to the conference website. The deadline for abstract submission is 15 November.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023